Openbookopenbook
Equity
MXCT
+0.0 · +0.00%
GBX · LSE

MaxCyte Inc(MXCT) Stock Analysis | Healthcare

GBX --+0.00%
Reward46Moderate
Risk44Moderate
75%Data
Thin -111% profit margin · Revenue down 8% YoY
Earnings Deterioration
Market Cap:161.75M
ⓘ
Reward Rating
46
Moderate
Reward Assessment
75% data coverage
Bottom 25% of stocksView factors
ⓘ
Risk Rating
44
Moderate
Risk Assessment
6 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on MXCT to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for MXCT, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: 537p.

What is MaxCyte Inc?

, a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally.

MXCT · Verdict

Moderate reward · moderate risk

MXCT stands out on balance sheet and valuation, but watch the cash flow signal.

Based on 88% data coverage

MXCT · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet86/100

    Current ratio 10.88

  • Valuation65/100

    Above average

Watchouts 3

  • Cash flow25/100

    -76% free-cash-flow margin

  • Profitability35/100

    -106% net margin · -20% ROE

  • Growth42/100

    Rev -1.7% CAGR · earnings +7.9%

Model-based scoring. For information only — not financial advice.

What is MaxCyte Inc?

, a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 161.75M.

Financial Highlights

Investment Breakdown

Growth
Growth trend is developing — watch for revenue consistency over upcoming quarters.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (46)

The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Medical Devices names that are close enough in size to make side-by-side comparison useful.

EKFMicro Cap / 109M market cap
EKF Diagnostics Holdings Plc
Compare
AOTIMicro Cap / 106M market cap
AOTI Inc
Compare
NIOXMicro Cap / 285M market cap
NIOX Group PLC
Compare
Company Information
SectorHealthcare
IndustryMedical Devices
Market Cap161.75M
P/E RatioN/A
Dividend YieldN/A
Beta1.041
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.